This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosenson, R. S. Articles by Mosca, L. J. Search for Related Content PubMed PubMed Citation Articles by Rosenson, R. S. Articles by Mosca, L. J.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1998;18:1902-1905.)
© 1998 American Heart Association, Inc.

Original Contributions

Hormone Replacement Therapy Improves Cardiovascular Risk by Lowering Plasma Viscosity in Postmenopausal Women

Robert S. Rosenson; Christine C. Tangney; Lori J. Mosca

From the Preventive Cardiology Center, Lipoprotein and Hemorheology Research Facility, and the Departments of Medicine, Pathology (R.S.R.), and Clinical Nutrition (C.C.T.), Rush Medical College, Chicago, Ill, and the Preventive Cardiology Research and Education Program (L.J.M.), The University of Michigan, Ann Arbor.

Abstract—Hormone replacement therapy may protect against cardiovascular disease through several mechanisms that have variable actions on the major determinants of plasma viscosity. Plasma viscosity is an important predictor of incident and recurrent cardiovascular events and mortality in coronary heart disease patients. The effect of estrogen alone or in combination with progestin on plasma viscosity is not known. Using a randomized, double-blind design, we examined the impact of the following daily hormone regimens on plasma viscosity in 23 women: (1) 1 mg estradiol and 2.5 mg medroxyprogesterone (n=7); (2) 1 mg estradiol alone (n=8); and (3) placebo (n=8). Plasma viscosity, fibrinogen, and standard lipoprotein levels were determined at baseline and after 12 weeks of intervention. Plasma viscosity was measured at 37°C with a coaxial microviscometer. Fibrinogen was measured by the Clauss method. Significant changes in plasma viscosity (mPa · s) levels occurred among treatment groups (P<0.01) after the intervention. Plasma viscosity was significantly reduced with estrogen replacement therapy (P<0.01). These data demonstrate that estrogen replacement therapy lowers plasma viscosity. This study suggests an additional mechanism for the cardiovascular protection conferred to postmenopausal women on estrogen replacement therapy.

Key Words: hormone replacement therapy • estrogen • plasma viscosity • coronary heart disease risk

This article has been cited by other articles:

				Y. Nakano, T. Oshima, R. Ozono, A. Ueda, Y. Oue, H. Matsuura, M. Sanada, K. Ohama, K. Chayama, and M. Kambe Estrogen replacement suppresses function of thrombin stimulated platelets by inhibiting Ca2+ influx and raising cyclic adenosine monophosphate Cardiovasc Res, February 15, 2002; 53(3): 634 - 641. [Abstract] [Full Text] [PDF]

				M. D. P. Luyer, S. Khosla, W. G. Owen, and V. M. Miller Prospective Randomized Study of Effects of Unopposed Estrogen Replacement Therapy on Markers of Coagulation and Inflammation in Postmenopausal Women J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3629 - 3634. [Abstract] [Full Text] [PDF]

				L. Mosca The Role of Hormone Replacement Therapy in the Prevention of Postmenopausal Heart Disease Arch Intern Med, August 14, 2000; 160(15): 2263 - 2272. [Abstract] [Full Text] [PDF]

				Hormone Therapy Lowers Plasma Viscosity Journal Watch Women's Health, February 1, 1999; 1999(201): 13 - 13. [Full Text]